Skip to main content
. 2020 Oct 29;12(11):1031. doi: 10.3390/pharmaceutics12111031

Figure 3.

Figure 3

NUC-1031 overcomes the main resistance mechanisms associated with gemcitabine, in particular, transport via human equilibrative nucleoside transporters (hENT1), breakdown via cytidine deaminase (CDA), and activation via deoxycytidine kinase (dCK). NUC-1031 is designed to create and retain higher drug levels concentrations of metabolite inside the tumor in comparison to gemcitabine. The promoieties are shown with a dashed red line.